Lexeo Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

• Lexeo Therapeutics Inc LXEO.OQ reported a quarterly adjusted loss of 99 cents​​ per share for the quarter ended March 31, lower than the same quarter last year, when the company reported EPS of -77 cents. The mean expectation of seven analysts for the quarter was for a loss of 78 cents per share. Wall Street expected results to range from -83 cents to -69 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Lexeo Therapeutics Inc's reported EPS for the quarter was a loss of 99 cents​.

• The company reported a quarterly loss of $32.66 million.

• Lexeo Therapeutics Inc shares had fallen by 22.5% this quarter and lost 59.1% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 1.5% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Lexeo Therapeutics Inc is $21.00

This summary was machine generated from LSEG data May 12 at 02:08 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)